Percutaneous Trans-facet Spine Fixation
Launched by MAHMOUD MASSOUD · May 24, 2025
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Massoud-Goel' as rationale treatment for treatment spinal degeneration affected spinal segments using trans-articular screws, without physically distracting the facets, or removal of any part of the bone or ligament.
Following fixing of the segment, all the secondary phenomenon reverse, effectively increasing the canal size and reversing the effects of spinal degeneration and spinal canal stenosis.
Stabilizes the region and provides an environment for resorption of the herniated disc and ultimate arthrodesis of the spinal segments.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • For Lumbar Sub-axial cervical instability Clinical radicular symptoms can indicate the level of spinal instability. The presence of osteophytes. Reduction of the intervertebral disc space. Disc prolapse. Ligamentum flavum buckling. For atlantoaxial instability Cervical myelopathy clinical Alteration of atlantodental interval on dynamic flexion-extension images.
- Exclusion Criteria:
- • 1. Cauda equine syndrome
- • 2. Progressive motor weakness
- • 3. Failed damage control method
- • 4. Spondylolisthesis, Spondyolysis.
About Mahmoud Massoud
Mahmoud Massoud is a dedicated clinical trial sponsor with a commitment to advancing medical research and improving patient outcomes. With a focus on innovative therapies and evidence-based practices, Mahmoud Massoud oversees the design, implementation, and management of clinical trials across various therapeutic areas. His expertise in regulatory compliance, patient safety, and data integrity ensures that all trials adhere to the highest ethical standards and scientific rigor. By fostering collaboration among multidisciplinary teams, Mahmoud Massoud strives to accelerate the development of groundbreaking treatments that address unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cairo, Shorouk, Egypt
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported